NASDAQ
23.22USD
+0.01 (+0.04%)
Dots are scored news catalysts — size = impact, color = sentiment. Tap one to read it.
Market cap
2.4B
P/E
—
EPS
—
Beta
1.79
52W range
8.195-25.085
Day range
22.64–23.31
Open
22.96
Prev close
23.21
Volume
1.3M
Avg volume
2M
Dividend
0.00
IPO
2020-07-24
https://www.globenewswire.com/news-release/2026/08/04/3338014/0/en/Nurix-Therapeutics-Announces-First-Patient-Enrolled-in-Registrational-Phase-3-DAYBreak-CLL-306-Trial-of-Bexobrutideg-in-Relapsed-Refractory-Chronic-Lymphocytic-Leukemia-Small-Lymph.html · 8/4/2026+0.80
https://www.zacks.com/stock/news/2943766/nurix-therapeutics-nrix-soars-16-4-is-further-upside-left-in-the-stock?cid=CS-STOCKNEWSAPI-FT-tale_of_the_tape|daily_price_change_5%-2943766 · 6/26/2026+0.90
https://www.schaeffersresearch.com/content/news/2026/06/08/nurix-therapeutics-stock-pops-on-roche-partnership · 6/8/2026+1.00
https://www.globenewswire.com/news-release/2026/06/08/3307775/0/en/nurix-therapeutics-announces-global-collaboration-with-roche-to-co-develop-and-co-commercialize-potential-best-in-class-btk-degrader-bexobrutideg-across-malignant-hematology-immuno.html · 6/8/2026
https://247wallst.com/investing/2026/05/18/7-healthcare-ai-stocks-under-50-with-huge-upside-potential/ · 5/18/2026+0.50
https://seekingalpha.com/article/4891528-nurix-therapeutics-inc-nrix-presents-at-25th-annual-needham-virtual-healthcare-conference · 4/17/2026+0.10
https://seekingalpha.com/article/4889607-nurix-strong-buy-bexobruditeg-development-and-dual-degrader-zelebrudomide · 4/9/2026+0.90
https://www.fool.com/coverage/filings/2026/02/22/nurix-stock-is-down-6-this-past-year-but-one-biotech-fund-still-boosted-its-bet-by-usd63-million/ · 2/22/2026+0.40
https://www.zacks.com/stock/news/2824704/nurix-therapeutics-inc-nrix-reports-q4-loss-misses-revenue-estimates?cid=CS-STOCKNEWSAPI-FT-tale_of_the_tape|yseop_template_4-2824704 · 1/28/2026+0.10
https://seekingalpha.com/article/4860430-nurix-therapeutics-why-this-company-could-double-in-value · 1/16/2026+0.90
https://seekingalpha.com/article/4859034-nurix-therapeutics-inc-nrix-presents-at-44th-annual-j-p-morgan-healthcare-conference · 1/13/2026+0.20
https://www.globenewswire.com/news-release/2025/12/08/3201481/0/en/Nurix-Therapeutics-Presents-New-Data-from-the-Phase-1-Trial-of-Bexobrutideg-NX-5948-in-Waldenstr%C3%B6m-Macroglobulinemia-at-the-67th-American-Society-of-Hematology-ASH-Annual-Meeting-a.html · 12/8/2025+0.80
Nurix Therapeutics, Inc., a clinical stage biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule and antibody therapies for the treatment of cancer, inflammatory conditions, and other diseases. The company develops NX-5948, an orally bioavailable BTK degrader, that is in Phase 2 clinical trials for the treatment of relapsed or refractory B-cell malignancies and autoimmune diseases; NX-2127, an orally bioavailable Bruton’s tyrosine kinase (BTK) degrader, that is in Phase Phase 1a/1b clinical trials for the treatment of relapsed or refractory B-cell malignancies; and NX-1607, an orally bioavailable Casitas B-lineage lymphoma proto-oncogene-B (CBL-B) inhibitor, that is in Phase 1a/1b clinical trials to treat immuno-oncology indications. It is also developing NX-0479/GS-6791, a IRAK4 degrader for the treatment of rheumatoid arthritis and other inflammatory diseases. The company has a strategic collaboration agreement with Gilead Sciences, Inc. (Gilead), Sanofi S.A. (Sanofi), and Pfizer Inc. (Pfizer) for co-development and co-commercialization for multiple drug candidates. The company was formerly known as Nurix Inc. and changed its name to Nurix Therapeutics, Inc. in October 2018. Nurix Therapeutics, Inc. was incorporated in 2009 and is headquartered in Brisbane, California.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
